This is a short guide outlining some of the key legal developments in the life sciences sector in 2013.
The developments include a proposed modification to the HSR Form that would impact reporting requirements, AIA’s First-Inventor-to-File provisions, Federal Circuit cases to watch, Reverse-Payment legislation, proposed State legislation concerning the substitution of biosimilar products, the US Federal Excise Tax on medical devices sales and the FDA’s draft guidance for the evaluation and labeling of abuse-deterrent opioids.
For further information or advice, please contact your usual contact at Mayer Brown or:
You have no pages selected. Please select pages to email then resubmit.